Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro. The gene discussed is NFKB1; the disease is non-small cell lung carcinoma.